Study summary
Benralizumab matched mepolizumab in EGPA and let more people stop steroids
59%in remission with benralizumab, vs 56% with mepolizumab
What was tested
Benralizumab, which removes eosinophils, against mepolizumab, which blocks IL-5, for relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).
What they found
- Remission at weeks 36 and 48 was 59% vs 56% (non-inferior).
- Complete steroid withdrawal was 41% vs 26%.
- Benralizumab is given every 4 weeks as one injection.
What it means
Gives EGPA patients a second targeted option.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.